{
  "contract_id": "BIOAMBERINC_04_10_2013-EX-10.34-DEVELOPMENT AGREEMENT (1)_cleaned",
  "original_file": "BIOAMBERINC_04_10_2013-EX-10.34-DEVELOPMENT AGREEMENT (1)_cleaned.txt",
  "chunk_size": 1000,
  "chunk_overlap": 200,
  "total_chunks": 35,
  "chunks": [
    "Exhibit 10.34\n[SECTION] DEVELOPMENT AGREEMENT\nThis Development Agreement (\"Development Agreement\") is entered into on April 15 , 2010 (\"EffectiveDate\") by and between Cargill, Incorporated through its Bio Technology Development Center, having its principal place of business at 15407 McGinty Road West, Wayzata, Minnesota 55391 USA (\"Cargill\") and Bioamber S.A.S., having a place of business at Route de Bazancourt, F-51110, Pomacle France (\"Bioamber\"). Bioamber and Cargill shall be referred to individually as \"Party\" and collectively as \"Parties\", as required by text.\nBackground\nCargill and Bioamber mutually agree as follows:\n A. Cargill has developed a yeast strain designated CB1 (\"CB1\") for fermenting dextrose and/or mixed sugar streams and related research tools for modifying CB1,which are protected by Licensed Patents (as defined in Section 2.5 below).",
    "B. Bioamber desires to engage Cargill to further develop or modify CB1 with the goal of fermenting dextrose and/or mixed sugar streams to produce succinic acid and salts thereof.\n C. The Parties desire to grant each other certain rights to use the further developed or modified CB1 as well as other technology that is developed in the course of the work as provided in this Development Agreement for research purposes only.",
    "1. Scope of Work Plan 1.1 Cargill agrees to perform the services to develop or modify CB1 to produce succinic acid and salts thereof using dextrose (defined as glucose) and/or sucrose as the fermentation feedstock (\"Work Plan\"). The Work Plan is more fully described in Exhibit A, which is hereby incorporated by reference into this Development Agreement. CB1 that has been further developed or modified (or the like) under the Work Plan shall be referred to as \"Modified CB1\". Any changes to the Work Plan must be in writing and signed by both Cargill and Bioamber and may be subject to incremental fees depending on resource requirements.\n1.2 In agreeing to perform the Work Plan, Cargill represents and warrants that:\n 1.2.1 Cargill has the capability, experience, and means necessary to perform the Work Plan, and the Work Plan will be performed using personnel, equipment, and material qualified and suitable to perform the Work Plan requested;\nth",
    "th\n 1.2.2 Cargill will provide properly trained and informed personnel, and Cargill will be solely responsible for the negligent acts, errors and omissions of its employees, subcontractors, and agents and for any other person performing services under this Development Agreement at the direct request of Cargill;\n 1.2.3 Cargill will perform the Work Plan in a workmanlike manner with reasonable skill and care ordinarily exercised by members of the profession practicing under similar conditions and in accordance with accepted industry practices and professional guidelines;\n 1.2.4 Subject to Section 13.1, Cargill has in effect and will maintain in effect all permits, licenses and other authorizations necessary to perform the Work Plan; and",
    "1.2.5 No other party has rights to its services as described in the Work Plan, and that a work assignment from any third party shall not be accepted, or work by Cargill aloneshall not be conducted, to develop CB1 or other microorganisms that will be used to (a) directly produce succinic acid and salts thereof, or (b) indirectly produce succinic acid and salts thereof (for example, Cargill may develop microorganisms to produce precursors of succinic acid, such as fumaric acid and malic acid, so long as such precursors are not converted to succinic acid, such as by chemical modification), for the Term (as defined in Section 10.1) of this Development Agreement. For purposes of clarity, and as examples, Cargill may sell dextrose as fermentation feedstock to third parties, who may use such dextrose to produce succinic acid; also, Cargill may modify starches to make succinic acid starch derivatives.",
    "2. Fees and Milestones 2.1 Bioamber shall pay Cargill Two Hundred Fifty Thousand U.S. Dollars ($250,000.00) within thirty (30) days of the execution of this Development Agreement.\n2.3 Bioamber shall also pay Cargill within thirty (30) days of achieving each of the milestones summarized below and more fully described in the Work Plan found in Exhibit A. For purposes of clarity, payment is triggered [***]. Further, each of the Milestones and Target Dates may be changed according to the needs of the Work Plan and upon written agreement by the parties.\nMilestone Target Date Payment Milestone 1: Proof of Concept 12 months after Effective Date US $250,000.00 Milestone 2: CB1 Strain Development 30 months after Effective Date US $300,000.00 Milestone 3: CB1 Strain Optimization 42 months after Effective Date US $500,000.00\n2.4 Missed Milestones.",
    "2.4.1 In the event Cargill does not achieve a given Milestone provided in Section 2.3 by the Target Date listed in Section 2.3 or modified Milestone and modified Target Date as agreed to by the Parties, and subsequently achieves such milestone as per the criteria described in Exhibit A, the payment for such missed milestone shall be due [***] and the amount due shall be [***] for every [***] beyond the Target Date. The Target Date for subsequent Milestones will be adjusted to reflect the date on which the Milestone was actually achieved. If a subsequent Milestone is achieved by the original Target Date listed in Section 2.3, Bioamber will pay Cargill the amount [***]. For purposes of clarity and as examples, if Milestones 1 and 2 were not delivered by the Target Dates, but Milestone 3 is delivered by or before the Target Date, then the total payments due to Cargill at that time would be [***] (a total payment of $[***])",
    ". Another example is if [***], the payment due at that time would be a total of $[***].",
    "2.4.2 In the event Cargill does not achieve a given Milestone provided in Section 2.3 by the Target Date listed in Section 2.3 or modified Milestone and modified Target Date as agreed to by the Parties, and Bioamber decides to commercialize Modified CB1, any outstanding milestone payments shall immediately become due such that the total payment due Cargill under this Development Agreement equals One Million Fifty Thousand U.S. Dollars (US $1,050,000.00).\n 2.4.3 Provided that Cargill has respected its undertakings set out in Section 1.2 of this Development Agreement, no other damages shall accrue to Cargill for not achieving a given Milestone other than provided in Sections 2.4.1, 2.4.2, and 2.5.",
    "2.6 Technology Transfer. In the event Milestone 3 is achieved, Cargill will provide up to [***] to assist in a successful transfer of the Modified CB1 technology to Bioamber in order to allow subsequent scale-up at the same FTE rate set forth in Section 2.2. For clarity, [***] per FTE per year equals US$[***] for this technology transfer).",
    "2.7 Scale-Up. Following the successful technology transfer, upon request by Bioamber and subject to Cargill's availability of appropriate resources, Cargill will enter at its sole discretion into a services agreement with Bioamber to assist in the fermentation scale-up of using Modified CB1 obtained under Milestones 2 and 3 for producing succinic acid and salts thereof at a single Bioamber facility or a facility designated by Bioamber. Cargill shall invoice Bioamber [***] U.S. Dollars (US$[***]) per man-day provided, not inclusive of taxes or other governmental fees, and further adjusted for inflation at the time it goes into effect. Cargill shall have no obligation to perform scale-up work at Cargill facilities.",
    "3. Alternative Feedstock. Bioamber also desires the right to further develop CB1 to utilize cellulosic biomass as the fermentation feedstock. Cargill hereby grants Bioamber the option to modify or convert the Work Plan to include the development or modification of CB1 capable of fermenting such cellulosic feedstock (\"Modified Work Plan\"). If such option is exercised, (a) the terms and conditions of this Development Agreement shall apply to the Modified Work Plan except (i) new, additional up-front and milestone payments shall apply as provided below, and (ii) any development work performed under the Modified Work Plan will be at a FTE rate which will be equivalent to the FTE rate provided in Section 2.2 above and further adjusted for inflation at the time it goes into effect; and (b) the commercial license attached as Exhibit D shall be expanded to include the resulting strain developed out of the Modified Work Plan with no additional change in the financial terms",
    ". Additionally, the additional up-front fee [***].",
    "Milestone using Alternative Feedstock Target Date Payment Up-front Payment TBD US $[***] Milestone 1: Proof of Concept TBD US $[***] Milestone 2: CB1 Strain Development TBD US $[***] Milestone 3: CB1 Strain Optimization TBD US $[***]\n5. Intellectual Property 5.1 Each party shall retain ownership of all intellectual property that it owned prior to the Effective Date.",
    "5.2 Improvements. Any invention or discovery relating to the Work Plan, in whole or in part, that is conceived during the term of this Development Agreement shall be an \"Improvement\". The scope for Improvements will be limited to the CB1 strain itself and the [***] (the \"Field\"), but shall exclude [***]. Bioamber will own any Improvement in the field of succinic acid and salts thereof and such Improvement shall be designated \"Bioamber Improvements\". Cargill will own any Improvement in all fields other than the field of succinic acid and salts thereof, subject to the rights provided in Section 5.2.1 below, and such Improvement shall be designated \"Cargill Improvements\". In the event it is not clear as to ownership of any Improvement as described in this Section 5.2, in other words, if it is not clear whether an invention or discovery is either a Bioamber Improvement or a Cargill Improvement, such Improvement shall be [***] and such Improvement shall be designated \"Joint Improvements\"",
    ". For purposes of clarity, as examples, Cargill Improvements are those inventions relating to fumaric acid and malic acid. Additionally, where an Improvement has applications both in the Field and outside the Field, then such Improvement, as it applies to the Field, shall be a Bioamber Improvement and, as it applies outside the Field, such Improvement shall be a Cargill Improvement.",
    "5.2.1 Cargill hereby grants Bioamber, and Bioamber hereby accepts, an exclusive, royalty-free license to Cargill Improvements and Joint Improvements for use in the Field during the term of this Development Agreement with a reservation of right for Cargill to practice such Cargill Improvements and Joint Improvements for use in the field of succinic acid and salts thereof during the term of this Development Agreement. Such use shall be for research purposes only with no rights to sublicense and with no \"have made\" rights. Cargill shall also grant a commercial license to Bioamber for Cargill Improvements and Joint Improvements under the terms and conditions of Exhibit D.\n 5.2.2 Bioamber hereby grants Cargill, and Cargill hereby accepts, an exclusive, worldwide, royalty-free license with an unlimited right to sublicense under and to Bioamber Improvements for use outside the Field during the term of this Development Agreement. Such use shall be for research purposes only.",
    "5.2.4 If Cargill waives its option to prepare and prosecute a patent application in accordance with Section 5.2.3 and elects not to file such a patent application or elects to allow any such patent application or issued/granted patent to become abandoned or lapse, Cargill shall give Bioamber notice of such election promptly and at least two (2) months prior to the first date that action must be taken to avoid such abandonment or lapse. Bioamber shall have the right to take over at its sole expense the filing, prosecution or maintenance of any such patent application and Bioamber shall keep Cargill informed of Bioamber's filing, prosecution, and maintenance activities. All out-of-pocket expenses of Cargill shall be reimbursed by Bioamber. Bioamber shall have no liability to Cargill for Bioamber's acts or failure to act with respect to such patent application or issued/granted patent.",
    "5.2.5 Cargill shall have the sole power to bring and/or settle suits for infringement of any and all patent applications and/or patents on Improvements, regardless of ownership; provided, however, if required by law, Cargill shall join Bioamber, and Bioamber shall be joined, in such suits. Cargill shall control any such suits and shall bear all expenses related to any such suits. Bioamber shall provide any assistance reasonably requested in prosecuting and enforcing any and all patent applications and/or patents on Improvements. In the event Cargill elects not to initiate and prosecute suits for infringement of any patent application/and or patent onImprovement within the Field, then with sixty (60) days prior written notice to Cargill, Bioamber shall be entitled to initiate and prosecute such suits. For purposes of clarity, within such sixty (60) day period, Cargill shall be entitled to initiate and prosecute such suits.",
    "5.2.6 Cargill shall have the sole power to settle suits for infringement of the Licensed Patents. Cargill will in good faith consider enforcement requests from Bioamber.\n5.3 In consideration of the ownership rights granted to Bioamber under this Section 5, and the licenses granted to Bioamber under this Section 5 and the Commercial License attached as Exhibit D, Bioamber agrees to the payment terms and its other obligations contained in the attached Commercial License.",
    "6. WRF Patents. Washington Research Foundation (WRF) is the owner of several patents relating to the expression of polypeptides in yeast (\"WRF Patents\"). Prior to transferring CB1 or any other yeast strain to Bioamber, Bioamber shall provide to Cargill a letter from WRF stating that Bioamber has a license to the WRF Patents (\"Bioamber-WRF License\"). Upon receipt of such letter, Cargill will transfer CB1 to Bioamber for Bioamber's use of the strain commensurate with and in accordance with the Bioamber-WRF License. Cargill shall have no liability to Bioamber for Bioamber's acts or failure to act with respect to the WRF Patents. 7. Warranties. Except as provided in Section 1.2 of this Development Agreement, Cargill makes no representations or warranties, express or implied, with respect to the services provided under this Development Agreement and with respect to the subject matter of this Development Agreement",
    ". The services are provided \"as is\" and Bioamber acknowledges that it bears all responsibility and accountability for evaluating, approving, and implementing any of results resulting from this Development Agreement.",
    "8. Indemnification. Bioamber and Cargill agree to waive any and all claims against each other for consequential, punitive, incidental, special, or other forms of \"exemplary\" losses whether arising in contract, warranty, tort (including negligence), strict liability, or otherwise, including any losses relating to lost use, lost profits, lost business, damage to reputation, or lost or diminished financing unless such claims are based on a Party's gross negligence or willful misconduct. 9. Notices. All notices or other communication must be in writing and delivered by (a) personal delivery, (b) reputable overnight delivery service, or (c) facsimile or e-mail, confirmed under clause (a) or clause (b), and addressed in each case as set forth below:\nIf to Cargill: If to Bioamber:",
    "If to Cargill: If to Bioamber:\nCargill, Incorporated Bioamber S.A.S. Bio Technology Development Center 1250 Rene-Levesque West 15285 Minnetonka Blvd. Suite 4110 Minnetonka, Minnesota 55345 USA Montreal, Quebec Canada H3B 4W8 Fax: 952-742-0540 Fax: 514-844-1414 Attention: Pirkko Suominen Attention: Laurent Bernier\nWith copy to: Cargill, Incorporated Law Department / Mailstop 24 15407 McGinty Road West Wayzata, Minnesota 55391 USA Fax: 952-742-6349 Attention: Bio TDC IP Lawyer\nWith copy to: Boivin Desbiens Sencal, g.p. 2000-2000 McGill College Suite 2000 Montreal, QC, Canada H3A 3H3 Fax: 514-844-5836 Attention: Thomas Desbiens\n10. Term and Termination.",
    "10. Term and Termination.\n10.1 This Development Agreement will begin on the Effective Date and continue for four (4) years unless earlier terminated pursuant to Section 10.2, or unless the parties extend the term by mutual written Development Agreement (\"Term\"). 10.2 Either Party may terminate this Development Agreement by giving written notice to the other Party, (a)in the event the other Party's bankruptcy, insolvency, or the filing of a petition therefore; and (b) the other Party materially defaults in the performance of its obligations hereunder. This Development Agreement shall also terminate upon mutual written agreement by the Parties. Further, in the event there is a dispute as to whether or not Cargill has missed a certain Milestone, then the Target Date for that Milestone shall be tolled until the Parties, acting in good faith, have settled such dispute in writing between themselves or through an independent expert.",
    "11. Independent Contractor. Nothing in this Development Agreement is to be construed to deem the relationship between the parties to be one of master/servant, principal/agent, or employer/employee. To the contrary, the relationship of Cargill to Bioamber is that of independent contractor, and Cargill will have no authority to (i) make any binding decision for, or on behalf of, Bioamber or (ii) commit Bioamber to any contract, obligation, debt, or other liability. None of Cargill's employees will be deemed to be employees of Bioamber. 12. Publicity. Any public statements related to work performed under this Development Agreement, including public statements related to the existence of this Development Agreement itself, will only be made after the prior written consent of both Parties concerning timing, content, and audience.\n13. Miscellaneous.",
    "13. Miscellaneous.\n13.1 Third Party Patents. In addition to the WRF Patents as described more fully in Section 6, the CB1 Team of the Bio Technology Development Center of Cargill represents that, to the best of its knowledge as of the Effective Date, the patents and patent applications of third parties that could impact the Work Plan and the commercialization thereof are provided in Exhibit E (\"Third Party Patents\"). Cargill shall have no liability to Bioamber for Bioamber's acts or failure to act with respect to such Third Party Patents. The Parties shall meet regularly throughout the Term of this Development Agreement to determine whether or not licenses to Third Party Patents are needed to perform or continue to perform the Work Plan and the next steps if such licenses are needed.\n13.2 Governing Law. This Development Agreement shall be governed by and construed in accordance with the laws of the State of Minnesota, United States of America, disregarding its conflicts of law rules.",
    "13.3 Assignment. Neither Party shall assign this Development Agreement or the obligations contained herein without the express written consent of the other Party.\n13.4 Waiver. The failure of either Party to insist in any one or more instances upon performance of any terms or conditions of this Development Agreement, is not to be construed as a waiver of future performance of any such term, covenant, or condition, but the obligations of either Party with respect thereto will continue in full force and effect. No waiver will be effective unless in writing and signed by the waiving Party.",
    "13.5 Amendment. No amendment, modification, or waiver of the terms of this Development Agreement shall be binding unless placed in writing and duly executed by the Parties' authorized representatives. 13.6 Severability. All provisions contained herein are severable, and in the event any of them is held to be invalid by any competent court or arbitrator, this Development Agreement is to be interpreted as if such invalid provision were not contained herein.",
    "13.9 Bioamber Non-Compete Commitment. Bioamber will not itself or with or through third parties engage in the development of biocatalysts other than E. coli for the production of succinic acid or salts thereof, except for the development activities under the terms and conditions of this Development Agreement. This obligation endures for the Term of this Development Agreement. Notwithstanding the above, Bioamber shall be permitted to evaluate other biocatalysts, but shall not undertake development of such biocatalysts. The purpose of such evaluations shall be to identify and eventually secure alternative technologies, in the event that the CB1 development program is not successful",
    ". The purpose of such evaluations shall be to identify and eventually secure alternative technologies, in the event that the CB1 development program is not successful. As such, Bioamber shall cease within 30 days any further funding and development of a biocatalyst, including but not limited to the genetic modification or the optimization of fermentation conditions, when such biocatalyst has demonstrated the ability to produce succinic acid at a concentration above [***] grams per liter. This restriction shall apply to any succinic acid biocatalyst other than E. coli, be it a biocatalyst developed in-house, licensed-in, or under development at a third party lab that is funded by Bioamber or to which Bioamber has secured a future right or right of first refusal through direct payment, in kind contribution, grant, gift, differed payment or commitment to a future payment.",
    "The Parties, through their authorized representatives, hereby agree to the terms and conditions of this Development Agreement.\nCARGILL, INCORPORATED Bio Technology Development Center BIOAMBER S.A.S.\n/s/ Jack Staboch /s/ Jean-Franois Huc Signature Signature\nVP BioTDC Director General Title Title\n4/16/10 April 15, 2010 Date Date\nExhibit A Work Plan Milestones\n[***]\n[SECTION] MILESTONE 1\n[***] Time to achieve: Month 12\n[SECTION] MILESTONE 2\n[***] Time to achieve: Month 30\n[SECTION] MILESTONE 3\nExhibit B Cargill Patents and Patent Applications\nPublication # Title Filing Date Expiration Date\n[***]\nPublication # Title Filing Date Expiration Date\n[***]\nPublication # Title Filing Date Expiration Date\n[***]\nPublication # Title Filing Date Expiration Date\n[***]\nPublication # Title Filing Date Expiration Date\n[***]\nPublication # Title Filing Date Expiration Date\n[***]\nExhibit C Licensed Tool Kit\nBasic Package Content:\nAdditional Fee Option Content:\n -  [***] -  [***] -  [***] -  [***] -  [***]",
    "[***]\nPublication # Title Filing Date Expiration Date\n[***]\nExhibit C Licensed Tool Kit\nBasic Package Content:\nAdditional Fee Option Content:\n -  [***] -  [***] -  [***] -  [***] -  [***]\n -  The price will be negotiated, but as of the Effective Date of this Agreement, the fair market value is base package price of US $[***]\n -  Genome sequence of CB1, including assembly and annotations as is Cargill's state of the art at the time of the request.\n -  The price will be negotiated, but as of the Effective Date of this Development Agreement, the fair market value is price of US $[***]\n[SECTION] EXHIBIT D\nEXHIBIT E Third Party Patents relating to the Work Plan\nThird Party Patents relating to Modified Work Plan\nPublication number and title Assignee [***]\nPublication number and title Assignee [***]\nEXHIBIT F Cargill's Guiding Principles\nCargill's Compliance Policy on Intellectual Property",
    "Publication number and title Assignee [***]\nPublication number and title Assignee [***]\nEXHIBIT F Cargill's Guiding Principles\nCargill's Compliance Policy on Intellectual Property\n -  Cargill will comply with the laws of all countries to which it is subject. -  Cargill will not knowingly assist any third party to violate any law of any country, by creating false documents or by any other means. -  Cargill will not pay or receive bribes or participate in any other unethical, fraudulent, or corrupt practice. -  Cargill will always honor all business obligations that it undertakes with absolute integrity. -  Cargill will keep its business records in a manner that accurately reflects the true nature of its business transactions.",
    "-  Cargill managers and supervisors will be responsible that employees, consultants and contract workers under their supervision are familiar with applicable laws and company policies and comply with them. Further, they will be responsible for preventing, detecting, and reporting any violations of law of Cargill policies. -  Cargill employees will not become involved in situations that create a conflict of interest between the company and the employee. -  Every year, all Cargill employees sign an agreement to live these principles."
  ]
}